SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/17/2017 5:57:05 PM - Followers: 46 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:32:02 PM
TROV News: Current Report Filing (8-k) 08/16/2017 08:08:52 AM
TROV News: Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combi... 08/16/2017 08:00:00 AM
TROV News: Current Report Filing (8-k) 08/09/2017 04:38:44 PM
TROV News: Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results 08/09/2017 04:26:00 PM
News News Alert: Statement of Changes in Beneficial Ownership (4) 08/17/2017 04:32:02 PM
PostSubject
#897   Huge Buy on 08/15/2017 by Trovagene's CEO..... n3m3sis 08/17/17 05:57:05 PM
#896   Hedge fund accumulation? Todays news could propel a biotechnician 07/27/17 09:59:47 AM
#895   Any news could send the stock over $2, Maple tree 07/14/17 03:34:27 PM
#894   TROV will go to multidollar range and it Maple tree 07/14/17 09:40:23 AM
#893   Good opportunity to load this morning Maple tree 07/14/17 09:10:10 AM
#892   Gap up stock!! Ericj5592 07/12/17 09:12:14 AM
#891   News is out folks... BreezyP250 07/12/17 08:08:58 AM
#890   Chart looks good for a move up now. batmen 07/06/17 03:11:53 AM
#889   That was yesterday. james_west_1965 06/29/17 10:36:48 AM
#888   I thought you said....... n3m3sis 06/29/17 09:14:45 AM
#887   Big news! james_west_1965 06/29/17 08:53:18 AM
#886   Sure..... Don't look like it to me. :) n3m3sis 06/28/17 12:46:55 PM
#885   TROV has flat-lined. james_west_1965 06/28/17 12:38:25 PM
#884   Mainly institutions and Hedge fund's, yes. n3m3sis 06/27/17 05:59:07 AM
#883   So because of the rebalancing of the index batmen 06/26/17 01:59:28 PM
#882   I beg to differ with that assessment. n3m3sis 06/26/17 05:04:34 AM
#881   If this was a great buy last week batmen 06/26/17 03:53:15 AM
#880   1 second after 4:00 pm 2,200,000 shares sold Cartman1 06/23/17 10:48:11 PM
#879   2.2m dump after hours. You longs are screwed Gaggles1 06/23/17 10:06:33 PM
#878   So what do you mean by this that batmen 06/23/17 08:12:26 PM
#877   Go trov europtiger 06/23/17 10:40:37 AM
#876   * * $TROV Video Chart 06-22-17 * * ClayTrader 06/22/17 05:04:20 PM
#875   The shorts sellers are so greedy, that they.... n3m3sis 06/22/17 03:41:09 PM
#874   Does anyone see this stock going to $2??? PennytheStockPicker 06/22/17 12:26:53 PM
#873   I know,Got a stop in 1,08 Gltu europtiger 06/22/17 10:06:21 AM
#872   Be Careful..... n3m3sis 06/22/17 09:49:15 AM
#871   In 1,23 europtiger 06/22/17 09:44:58 AM
#870   BUY ALERT -Chief Executive Officer, Bill Welch, will ice1234 06/13/17 01:09:47 PM
#869   * * $TROV Video Chart 06-06-17 * * ClayTrader 06/06/17 05:03:16 PM
#868   Okay a great green day$$$ JMO running bull 06/06/17 04:11:10 PM
#867   Had one of its best days in forever Tdash 04/13/17 03:38:11 PM
#866   So, no longer investment worthy, whats timing on ringao 04/12/17 06:44:03 AM
#865   I guess they are doing such a bang stockmule 04/11/17 09:17:43 AM
#864   wow ringao 04/11/17 06:49:30 AM
#863   Tough one to take, sold most right after ringao 03/23/17 07:31:45 AM
#862   On watch for bottom bouncer Klinsmann 03/22/17 10:25:22 AM
#861   Where Welch goes a trail of destruction follows, stockmule 03/20/17 06:05:57 PM
#860   This has gotten hammered. Great test maybe cash stockmule 03/09/17 11:20:38 AM
#859   I loaded up on TrovaGene on friday, under briphelps 01/21/17 08:25:01 AM
#858   Reorganization. Elimination of ~ 20 employees. $4M Optionsrbest4u 12/13/16 05:29:04 PM
#857   Dont say I didnt try to help. Whoever Tdash 12/08/16 12:31:06 PM
#856   hmmm. This $2.40 entry might be the start Tdash 12/08/16 10:25:32 AM
#855   I agree and I'm with ya. People don't ringao 12/02/16 04:22:41 PM
#854   Had to buy massive amount of shares of briphelps 12/01/16 05:20:39 PM
#853   I've been following it for sometime. What makes briphelps 08/18/16 09:04:19 AM
#852   Personally, think this is in the process of Pepsiman2001 08/17/16 06:31:42 PM
#851   Diagnostic Performance of Urinary EGFR Testing in Lung briphelps 07/26/16 09:27:39 AM
#850   Feller, undiscovered gem. briphelps 07/25/16 08:58:30 AM
#849   http://moneymappress.com/mmp-research/_reports/MMPPremiums/MMP_TheComing303Windf briphelps 07/25/16 08:57:55 AM
#848   I wonder if Bill Palaton is going to FELLER 07/18/16 01:00:57 PM
PostSubject